HBC Immunology LLC is focused on discovery and development of peptides that normalize tumor micro-environments to improve immunotherapy and chemotherapy performance. Its lead assets are patented peptide analogs FT-002 and FT-005, derived from ProGo® Bioactive Peptides that modulate iron metabolism. The company plans to use the seed proceeds to commence preclinical animal trials and to demonstrate the bioactivity of the lead peptides in xenograft models of prostate cancer. HBCI’s first targeted indication is advanced prostate cancer, with ongoing in vitro work in breast and ovarian cancer, and an aim to move into earlier disease stages to improve patient quality of life and survival. The seed financing is expected to fund HBCI to a decision to open a US FDA IND by the end of 2024, and the company may increase the round through the end of October 2023. HBC Immunology is majority owned by Hofseth BioCare ASA, a Norwegian consumer and pet health ingredient supplier and incubator for pharmaceutical leads; HBC is headquartered in Ålesund, Norway with branches in Oslo, London, Zürich, Ningbo, New Jersey and Palo Alto and is listed on Oslo Børs under ticker "HBC."

Total raised

$1M

Funding rounds

1

Latest round

Seed

Latest activity

Aug 2023